|

by Angela Betsaida B. Laguipo, BSNB
April
22, 2020
from
News-Medical Website

Coronavirus
https://www.scientificanimations.com
CC BY-SA
The coronavirus disease (COVID-19)
continues to threaten millions of people across the globe, and
lockdowns appear set to remain in
place in many countries amid rising death tolls, as governments
decide whether to extend restrictions aimed at reducing the spread
of the virus.
Now, a new study (Patient-derived
Mutations impact the pathogenicity of SARS-CoV-2) reveals
that the novel coronavirus has mutated into at least 30
different genetic variants, affecting different parts of the
world.
The team of researchers, spearheaded by Chinese scientists Professor
Li Lanjuan and her colleagues at the Zhejiang University in
China, has found within a small pool of patients many mutations not
previously reported.
These mutations include
rare changes that scientists had never imagined could happen.
The novel coronavirus, now officially called the severe acute
respiratory coronavirus 2 (SARS-CoV-2),
is an RNA virus,
just like the viruses that cause measles and flu.
These viruses are
more prone to changes and mutations compared to DNA viruses.
As the SARS-CoV-2 ripples
across the globe, scientists worry that the virus will mutate into
something deadlier and become a more significant threat to
humanity.
Mutations and rapid
spread
To arrive at their findings, the researchers analyzed the strains
from the 11 randomly chosen COVID-19 patients from Hangzhou in
China, where there had been 1,264 confirmed cases.
They tested how the virus
can effectively infect and kills the cells in the body. The team
identified more than 30 different mutations of the virus,
wherein 19 were never seen before.
Some of the mutations boosted the ability of the virus to spread,
while others strengthened tits ability to invade cells. The team
found that the deadliest mutations were seen in the ones
spreading in Europe and New York.
On the other hand,
weaker strains were seen in some parts of the United States,
such as Washington State.
"Current genomic
survey data suggest that single nucleotide variants (SNVs) are
abundant.
However, no mutation
has been directly linked with functional changes in viral
pathogenicity," the researchers wrote on the paper.
The paper, which was
published in the online journal MedRxiv, highlights how studying the
mutations can help provide a basis for vaccine development.
The tricky part is with
more mutations happening. It will take some time before a vaccine
can be developed. This is the first study to provide an insight into
how a mutation could impact the severity of the disease.
For instance, the virus
in New York is stronger and more aggressive, and it has the highest
infection toll in the country.

MERS Virus Particles Colorized scanning electron micrograph
of
Middle East Respiratory Syndrome virus particles (yellow)
attached to the surface of an infected VERO E6 cell (blue).
Image
captured and color-enhanced at the
NIAID
Integrated Research Facility in Fort Detrick, Maryland.
Credit:
NIAID
However, the weaker mutation did not mean a lower risk for the
population.
Take, for example, two
patients in the study in Zhejian, who are in their 30s and 50s, had
contracted the weaker strain of the virus but became severely-ill.
Though the patients had
recovered, they required admission in the intensive care unit
(ICU).
The team also revealed that some of the most aggressive strains of
the coronavirus were able to generate 270 times the viral load of
the weaker strains.
Further, potent strains
kill human cells fastest.
"Therefore, we
provide direct evidence that the SARS-CoV-2 has acquired
mutations capable of substantially changing its pathogenicity,"
the team added.
The team believes the
previous mutations that were not reported could be the reason behind
the high death tolls in some parts of Europe and New York.
The United States now has
the highest number of confirmed cases and deaths, with 840,897 and
46,611, respectively.

SARS-CoV-2 viruses are binding to
ACE-2
receptors on a human cell,
the initial stage of COVID-19 infection.
Conceptual 3D illustration
credit: Kateryna Kon / Shutterstock
Effect of many
mutation variants
With many mutations occurring in the virus, it may become more
challenging to develop a vaccine that is effective in
preventing the coronavirus disease.
Patients with COVID-19
are being treated in hospitals using one treatment, regardless of
the strain they have. The researchers suggest that knowing the
different mutations can aid in providing the right treatment to
patients.
Also, they can determine
actions to battle the virus.
Though the need for treatment or vaccine is urgent amid the
coronavirus pandemic, it is essential to take into consideration the
accumulating mutations.
Globally, the death rate topped 177,000, while the number of
confirmed cases has reached a staggering 2.56 million people.
The United States and
some countries in Europe, such as,
Spain, France, Italy,
Germany, the United Kingdom, and Turkey,
...have reported the
highest number of cases.
Important
Notice
medRxiv publishes preliminary scientific reports that are not
peer-reviewed and, therefore, not be regarded as conclusive, guide
clinical practice/health-related behavior, or treated as established
information:
-
Source:
COVID-19 Dashboard by the Center for Systems Science and
Engineering (CSSE) at Johns Hopkins University (JHU) -
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
-
Journal
reference: Yao, H., Lu, X., Chen, Q., Xu, K., Chen, Y.,
Cheng, L., Liu, F., Wu, Z., Wu, H., Jin, C., Zhengm M., Wu,
N., Jiang, C., and Li, L. (2020).
Patient-derived mutations impact the
pathogenicity of SARS-CoV-2. MedRxiv.
|